Zimmer Biomet delivered a strong Q1 2026, with organic growth at the upper end of its guidance range and EPS benefiting from a one-time tariff refund. Management raised its EPS and FCF guidance but left revenue unchanged, citing its ongoing commercial transformation. The call highlighted the acceleration of its sales force specialization and the upcoming launch of the Monogram robot. Q1 organic sales grew 2.9% cc, with U.S. +3.2% and international +2.5%; U.S. knee growth was +2.2%.
Zimmer Biomet delivered a strong Q1 2026, with organic growth at the upper end of its guidance range and EPS benefiting from a one-time tariff refund. Management raised its EPS and FCF guidance but left revenue unchanged, citing its ongoing commercial transformation. The call highlighted the acceleration of its sales force specialization and the upcoming launch of the Monogram robot. Q1 organic sales grew 2.9% cc, with U.S. +3.2% and international +2.5%; U.S. knee growth was +2.2%.
Zimmer Biomet delivered a strong Q1 2026, with organic growth at the upper end of its guidance range and EPS benefiting from a one-time tariff refund. Management raised its EPS and FCF guidance but left revenue unchanged, citing its ongoing commercial transformation. The call…
Q1 organic sales grew 2.9% cc, with U.S. +3.2% and international +2.5%; U.S. knee growth was +2.2%.
Guidance · revenue to 2%
Company maintained full-year revenue guidance of 1-3% organically, raised EPS guide to $8.40-$8.55 and FCF growth to 9-11%.
Management highlighted strong double-digit growth in technology sales, including ROSA and T-Mini, and is preparing for the launch of Monogram, an AI-driven robotic system, with FDA approval expected in early 2027 and fully autonomous version in late 2027 or early 2028. They are investing in hiring over 200 robotic clinical sales reps by end of 2027 and have completed enrollment in a 102-patient cl
Despite beating expectations, management is maintaining a confident but measured tone, noting that the year is a transition period. While they raised EPS and FCF guidance, they left revenue unchanged, preferring to wait 90 days before reassessing.
Management did not provide specific capital expenditure figures but indicated ongoing investments in commercial channel, technology launches, and manufacturing footprint expansion to lower-cost geographies, impacting operating margins.
Management expressed confidence in strategic execution, highlighted strong first-quarter results, and reiterated commitments to transformation and innovation despite maintaining conservative guidance.
“The invalidation of the IEPA tariffs, which contributed about 20 cents to our results in the quarter. We were beyond that a little bit better on underlying performance as well.”
“In the territories where we did switch from non-dedicated to dedicated, we've seen fairly dramatic improvements in productivity. Nationwide, our average REV does run seven cases. Our lead competitor is in the 16, 17 cases per week range. I…”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $8.40–$8.55 | $8.48 | RAISED |
| Free cash flow | FY2026 | 9%–11% | 10% | RAISED |
| Revenue | FY2026 | 1%–3% | 2% | MAINTAINED |
The Monogram acquisition gives Zimmer Biomet a potentially disruptive robotic platform, launching in early 2027.
“Paragon 28 first quarter growth accelerated around 200 basis points from the fourth quarter of 2025 and is trending back towards double-digit growth performance.”
… repair solutions. Speaking of the latter, we're also teaming up with some of the world's leading researchers in this groundbreaking opportunity. It is inspiring to see how rapidly we're advancing our commitment to solving some of the key problems in orthopedics, whether it's awareness, safety, efficiency and outcomes, today and in the future. Lastly, on diversification, original acquisitions are all seeing positive momentum. Paragon 28 first quarter growth accelerated around 200 basis points from the fourth quarter of 2025 and is trending back towards double-digit growth performance. OrthoGrid delivered its strongest quarter to date with significant growth and accelerated adoption, solidifying OrthoGrid as a core driver of our digital ecosystem and anterior hip triple play. Finally, with enrollment complete in the monogram clinical study, we remain on track to bring this very exciting first-of-the-world technology to market. In conclusion, we are very proud of the progress that we're making so far in 2026. We continue to prioritize our go-to-market commercial transformation in the U.S., and we continue to focus on driving robust adoption of our new product innovation cycle. …